Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece

被引：0
|
作者：
Theodoros V. Giannouchos
Dimos-Dimitrios Mitsikostas
Robert L. Ohsfeldt
Athanassios Vozikis
Paraskevi Koufopoulou
机构：
[1] Texas A&M University,Department of Health Policy and Management, School of Public Health
[2] Texas A&M University,Population Informatics Lab
[3] National and Kapodistrian University of Athens,First Neurology Department, Aeginition Hospital, School of Medicine
[4] University of Piraeus,Laboratory of Health Economics and Management, Economics Department
[5] KAT General Hospital of Attica,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：979 / 990
页数：11
相关论文
共 50 条
  • [21] Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
    Gomez-Dabo, Laura
    Caronna, Edoardo
    Mas-de-les-Valls, Rut
    Gallardo, Victor J.
    Alpuente, Alicia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    TOXINS, 2024, 16 (05)
  • [22] METHODOLOGICAL CONSIDERATIONS FOR COST-EFFECTIVENESS ANALYSIS OF ONABOTULINUMTOXINA IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY
    Globe, D.
    Carlson, J.
    Patel, H.
    Colayco, D.
    Hansen, R. N.
    Watanabe, J.
    Sullivan, S. D.
    VALUE IN HEALTH, 2011, 14 (03) : A78 - A78
  • [23] CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
    Ghetti, Gianni
    Pradelli, Lorenzo
    Papageorgiou, Giannis
    Karpouzos, George
    Arikan, Yelda
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 97 - 109
  • [24] Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis
    Armanious, Mark
    Khalil, Nadia
    Lu, Yuanyuan
    Jimenez-Sanders, Rebecca
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2021, 35 (01) : 1 - 6
  • [25] COST-EFFECTIVENESS OF ONABOTULINUMTOXIN-A FOR THE PROPHYLAXIS OF CHRONIC MIGRAINE
    Ruggeri, M.
    Carletto, A.
    Marchetti, M.
    VALUE IN HEALTH, 2012, 15 (07) : A553 - A553
  • [26] A COST-EFFECTIVENESS ANALYSIS OF VARENICLINE VERSUS BUPROPRION AND NICOTINE REPLACEMENT THERAPY IN GREECE
    Athanasakis, K.
    Igoumenidis, M.
    Karampli, E.
    Vitsou, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A493 - A493
  • [27] Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine
    Zhang, L
    Hay, JW
    VALUE IN HEALTH, 2004, 7 (03) : 289 - 289
  • [28] Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot® in the acute treatment of migraine
    Zhang, LH
    Hay, JW
    CNS DRUGS, 2005, 19 (07) : 635 - 642
  • [29] Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot® in the Acute Treatment of Migraine
    Lihua Zhang
    Joel W. Hay
    CNS Drugs, 2005, 19 : 635 - 642
  • [30] THE COST-EFFECTIVENESS OF FREMANEZUMAB IN PATIENTS WITH MIGRAINE AND PREVIOUS INADEQUATE RESPONSE TO ONABOTULINUMTOXINA FROM A UK HEALTHCARE SYSTEM PERSPECTIVE
    Skroumpelos, A.
    Freddi, M.
    Akcicek, H.
    Cohen, J. M.
    Driessen, M. T.
    VALUE IN HEALTH, 2021, 24 : S162 - S162
12345